PD1/PD-L1blockers trigger metastases
Drug Developers dealing with PD1-PDL1 checkpoint inhibitors must consider new safety problems associated with the hyped cancer meds.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Entries by Thomas Gabrielczyk
EIB incentivises bioeconomy investments
/in News/by Thomas GabrielczykThe European Investment Bank (EIB) has issued its first Sustainability Awareness Bond worth 500m to support investments into water projects – health and nutrition to follow.
New antibiotics on the block
/in News/by Thomas GabrielczykAround 300 international AMR experts met at ESCMID-ASM drug development conference in Lisbon to discuss the latest progress in the field.
Adaptimmune raises US$100m
/in News/by Thomas GabrielczykOxford-based Adaptimmune Therapeutics plc has raised US$100m in a registered direct offering of American Depositary Shares (ADS).
CAR-Ts: Novartis wins UK
/in News/by Thomas GabrielczykThe NHS England announces it will reimburse Novartis CAR-T cell therapy Kymriah as treatment for children with B cell acute lymphoblastic leukemia (ALL) that are refractory, in relapse post-transplant or […]
Evox raises 37m in Series B round
/in News/by Thomas GabrielczykExosome drug delivery specialist Evox Therapeutics Ltd has closed a 37.1m (£35.5m) Series B financing round led by Redmile Group and significant contributions from GV (Google Ventures) and Cowen Healthcare Investments.
Sanofi gets the EUs ok for caplacizumab
/in News/by Thomas GabrielczykThe EU approved Sanofis Cablivi (caplacizumab) as the first antibody therapeutic to treat acquired thrombotic thrombocytopenic purpura (aTTP) on Friday.
Cancer drug cures orphan disease skin damage
/in News/by Thomas GabrielczykAn FDA-approved cancer drug stops light sensitivity of the skin in Cockayne syndrome (CS), an ultra-rare hereditary disease characterised by premature aging, German researchers report.
Germany to pump 1bn into breakthrough innovation
/in News/by Thomas GabrielczykGermanys government announced that it will create an agency for breakthrough ("jump") innovation to foster technology transfer of risky research projects with high market potential into products.
Urovant Sciences licenses OAB gene therapy
/in News/by Thomas GabrielczykUrovant Sciences has licensed the global commercialisation rights for Ion Channel Innovations gene therapy hMaxi-K for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy.